articleThe Lancet OncologyOct 10, 2017GREEN OA

Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial

HAHussein A. TawbiMBMelissa BurgessVBVanessa BolejackBABrian A. Van TineSMScott M. Schuetze

The University of Texas MD Anderson Cancer Center · University of Pittsburgh · +14 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

1,405
total citations
FWCI
76.71
Percentile
100%
References
42
Citations per year

Authors

24

Topics & keywords

Topics
Keywords
  • Medicine
  • Sarcoma
  • Pembrolizumab
  • Soft tissue sarcoma
  • Bone Sarcoma
  • Surgery
  • Clinical endpoint
  • Soft tissue
No related works found for this paper.